Publicação

Susceptibility to lenacapavir among newly diagnosed HIV-positive patients followed up in Mozambique that presented with primary antiretroviral resistance to other classes

Ver documento

Detalhes bibliográficos
Resumo:Multidrug-resistant HIV patients have limited ART options. Lenacapavir (LEN) is a capsid inhibitor that exhibits substantial antiviral activity in patients with therapeutic failure but is also proposed for PrEP. Herein, we assessed LEN susceptibility among ART-naive HIV patients with drug resistance in Mozambique. In this study, 63 patients with DRM against PIs, NRTIs, NNRTIs, and INSTIs were included. The gag (p24) and env fragments were amplified with a low-cost in-house protocol and sequenced with nanopore. HIVDR database from Stanford University was used to assess LEN resistance and geno2pheno to assess viral tropism and protease/maturation inhibitor-associated mutations. A total of 59 patients were successfully sequenced. About 29% had DRMs to PIs, 5% to NRTI, 83% to NNRTI, and 2% to INSTI. No DRMs to LEN were detected. Additionally, 42% of the sequences presented protease/maturation inhibitor-associated mutations. A relationship was observed between the E138A/G mutation and protease/maturation inhibitors (p = 0.004). We identified changes at the first codon position of position 56 of the p24 gag gene, which represents a key site for resistance to LEN. Also, codon 66 was highly conserved. Our results support the potential effectiveness of lenacapavir as a PrEP regimen or rescue therapy for patients with at least one drug-resistance mutation.
Autores principais:Sebastião, Cruz S.
Outros Autores:Bathy, Jamila; Nhampossa, Tacilta; Santos, André; Miranda, Mafalda; Manhiça, Neusa Magode; Bila, Rubão; Vubil, Delfino; Seabra, Sofia; Martins, Maria Rosário O.; Giovanetti, Marta; Gomes, Perpétua; Pingarilho, Marta; Abecasis, Ana B.; Pimentel, Victor
Assunto:drug resistance mutations HIV-1 lenacapavir Mozambique
Ano:2025
País:Portugal
Tipo de documento:contribuição para revista
Tipo de acesso:acesso aberto
Instituição associada:Egas Moniz - Cooperativa de Ensino Superior, CRL
Idioma:inglês
Origem:Egas Moniz - Cooperativa de Ensino Superior, CRL
_version_ 1866413231759687680
author Sebastião, Cruz S.
author2 Bathy, Jamila
Nhampossa, Tacilta
Santos, André
Miranda, Mafalda
Manhiça, Neusa Magode
Bila, Rubão
Vubil, Delfino
Seabra, Sofia
Martins, Maria Rosário O.
Giovanetti, Marta
Gomes, Perpétua
Pingarilho, Marta
Abecasis, Ana B.
Pimentel, Victor
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author_facet Sebastião, Cruz S.
Bathy, Jamila
Nhampossa, Tacilta
Santos, André
Miranda, Mafalda
Manhiça, Neusa Magode
Bila, Rubão
Vubil, Delfino
Seabra, Sofia
Martins, Maria Rosário O.
Giovanetti, Marta
Gomes, Perpétua
Pingarilho, Marta
Abecasis, Ana B.
Pimentel, Victor
author_role author
contributor_name_str_mv Repositório Comum
country_str PT
creators_json_txt [{\"Person.name\":\"Sebastião, Cruz S.\"},{\"Person.name\":\"Bathy, Jamila\"},{\"Person.name\":\"Nhampossa, Tacilta\"},{\"Person.name\":\"Santos, André\"},{\"Person.name\":\"Miranda, Mafalda\"},{\"Person.name\":\"Manhiça, Neusa Magode\"},{\"Person.name\":\"Bila, Rubão\"},{\"Person.name\":\"Vubil, Delfino\"},{\"Person.name\":\"Seabra, Sofia\"},{\"Person.name\":\"Martins, Maria Rosário O.\"},{\"Person.name\":\"Giovanetti, Marta\"},{\"Person.name\":\"Gomes, Perpétua\"},{\"Person.name\":\"Pingarilho, Marta\"},{\"Person.name\":\"Abecasis, Ana B.\"},{\"Person.name\":\"Pimentel, Victor\"}]
datacite.contributors.contributor.contributorName.fl_str_mv Repositório Comum
datacite.creators.creator.creatorName.fl_str_mv Sebastião, Cruz S.
Bathy, Jamila
Nhampossa, Tacilta
Santos, André
Miranda, Mafalda
Manhiça, Neusa Magode
Bila, Rubão
Vubil, Delfino
Seabra, Sofia
Martins, Maria Rosário O.
Giovanetti, Marta
Gomes, Perpétua
Pingarilho, Marta
Abecasis, Ana B.
Pimentel, Victor
datacite.date.Accepted.fl_str_mv 2025-03-01T00:00:00Z
datacite.date.available.fl_str_mv 2026-05-26T14:08:02Z
datacite.date.embargoed.fl_str_mv 2026-05-26T14:08:02Z
datacite.rights.fl_str_mv http://purl.org/coar/access_right/c_abf2
datacite.subjects.subject.fl_str_mv drug resistance mutations
HIV-1
lenacapavir
Mozambique
datacite.titles.title.fl_str_mv Susceptibility to lenacapavir among newly diagnosed HIV-positive patients followed up in Mozambique that presented with primary antiretroviral resistance to other classes
dc.contributor.none.fl_str_mv Repositório Comum
dc.creator.none.fl_str_mv Sebastião, Cruz S.
Bathy, Jamila
Nhampossa, Tacilta
Santos, André
Miranda, Mafalda
Manhiça, Neusa Magode
Bila, Rubão
Vubil, Delfino
Seabra, Sofia
Martins, Maria Rosário O.
Giovanetti, Marta
Gomes, Perpétua
Pingarilho, Marta
Abecasis, Ana B.
Pimentel, Victor
dc.date.Accepted.fl_str_mv 2025-03-01T00:00:00Z
dc.date.available.fl_str_mv 2026-05-26T14:08:02Z
dc.date.embargoed.fl_str_mv 2026-05-26T14:08:02Z
dc.format.none.fl_str_mv application/pdf
dc.identifier.none.fl_str_mv http://hdl.handle.net/10400.26/63322
dc.language.none.fl_str_mv eng
dc.publisher.none.fl_str_mv Wiley
dc.rights.cclincense.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.subject.none.fl_str_mv drug resistance mutations
HIV-1
lenacapavir
Mozambique
dc.title.fl_str_mv Susceptibility to lenacapavir among newly diagnosed HIV-positive patients followed up in Mozambique that presented with primary antiretroviral resistance to other classes
dc.type.none.fl_str_mv http://purl.org/coar/resource_type/c_3e5a
description Multidrug-resistant HIV patients have limited ART options. Lenacapavir (LEN) is a capsid inhibitor that exhibits substantial antiviral activity in patients with therapeutic failure but is also proposed for PrEP. Herein, we assessed LEN susceptibility among ART-naive HIV patients with drug resistance in Mozambique. In this study, 63 patients with DRM against PIs, NRTIs, NNRTIs, and INSTIs were included. The gag (p24) and env fragments were amplified with a low-cost in-house protocol and sequenced with nanopore. HIVDR database from Stanford University was used to assess LEN resistance and geno2pheno to assess viral tropism and protease/maturation inhibitor-associated mutations. A total of 59 patients were successfully sequenced. About 29% had DRMs to PIs, 5% to NRTI, 83% to NNRTI, and 2% to INSTI. No DRMs to LEN were detected. Additionally, 42% of the sequences presented protease/maturation inhibitor-associated mutations. A relationship was observed between the E138A/G mutation and protease/maturation inhibitors (p = 0.004). We identified changes at the first codon position of position 56 of the p24 gag gene, which represents a key site for resistance to LEN. Also, codon 66 was highly conserved. Our results support the potential effectiveness of lenacapavir as a PrEP regimen or rescue therapy for patients with at least one drug-resistance mutation.
dirty 0
eu_rights_str_mv openAccess
format contributionToPeriodical
fulltext.url.fl_str_mv https://comum.rcaap.pt/bitstreams/bf9a9732-dff4-46ee-8c2e-e24139e44ee8/download
id em_7492e4ed4d5960fe2a7bbcfbfea4c7f1
identifier.url.fl_str_mv http://hdl.handle.net/10400.26/63322
instacron_str em
institution Egas Moniz - Cooperativa de Ensino Superior, CRL
instname_str Egas Moniz - Cooperativa de Ensino Superior, CRL
language eng
network_acronym_str em
network_name_str Egas Moniz - Cooperativa de Ensino Superior, CRL
oai_identifier_str oai:comum.rcaap.pt:10400.26/63322
organization_str_mv urn:organizationAcronym:em
person_str_mv Sebastião, Cruz S.
Bathy, Jamila
Nhampossa, Tacilta
Santos, André
Miranda, Mafalda
Manhiça, Neusa Magode
Bila, Rubão
Vubil, Delfino
Seabra, Sofia
Martins, Maria Rosário O.
Giovanetti, Marta
Gomes, Perpétua
Pingarilho, Marta
Abecasis, Ana B.
Pimentel, Victor
publishDate 2025
publisher.none.fl_str_mv Wiley
reponame_str Egas Moniz - Cooperativa de Ensino Superior, CRL
repository_id_str urn:repositoryAcronym:em
service_str_mv urn:repositoryAcronym:em
spelling engWileyengMultidrug-resistant HIV patients have limited ART options. Lenacapavir (LEN) is a capsid inhibitor that exhibits substantial antiviral activity in patients with therapeutic failure but is also proposed for PrEP. Herein, we assessed LEN susceptibility among ART-naive HIV patients with drug resistance in Mozambique. In this study, 63 patients with DRM against PIs, NRTIs, NNRTIs, and INSTIs were included. The gag (p24) and env fragments were amplified with a low-cost in-house protocol and sequenced with nanopore. HIVDR database from Stanford University was used to assess LEN resistance and geno2pheno to assess viral tropism and protease/maturation inhibitor-associated mutations. A total of 59 patients were successfully sequenced. About 29% had DRMs to PIs, 5% to NRTI, 83% to NNRTI, and 2% to INSTI. No DRMs to LEN were detected. Additionally, 42% of the sequences presented protease/maturation inhibitor-associated mutations. A relationship was observed between the E138A/G mutation and protease/maturation inhibitors (p = 0.004). We identified changes at the first codon position of position 56 of the p24 gag gene, which represents a key site for resistance to LEN. Also, codon 66 was highly conserved. Our results support the potential effectiveness of lenacapavir as a PrEP regimen or rescue therapy for patients with at least one drug-resistance mutation.application/pdfengSusceptibility to lenacapavir among newly diagnosed HIV-positive patients followed up in Mozambique that presented with primary antiretroviral resistance to other classesSebastião, Cruz S.Bathy, JamilaNhampossa, TaciltaSantos, AndréMiranda, MafaldaManhiça, Neusa MagodeBila, RubãoVubil, DelfinoSeabra, SofiaMartins, Maria Rosário O.Giovanetti, MartaGomes, PerpétuaPingarilho, MartaAbecasis, Ana B.Pimentel, VictorHostingInstitutionOrganizationalRepositório Comume-mailmailto:comum@rcaap.ptcomum@rcaap.ptISSNIsPartOf1096-9071DOIIsPartOf10.1002/jmv.703172026-05-26T14:08:02Z2025-032025-03-01T00:00:00ZHandlehttp://hdl.handle.net/10400.26/63322http://purl.org/coar/access_right/c_abf2open accessdrug resistance mutationsHIV-1lenacapavirMozambique484857 bytesother research producthttp://purl.org/coar/resource_type/c_3e5acontribution to journal2025-03http://creativecommons.org/licenses/by-nc-nd/4.0/http://purl.org/coar/access_right/c_abf2application/pdffulltexthttps://comum.rcaap.pt/bitstreams/bf9a9732-dff4-46ee-8c2e-e24139e44ee8/downloadJournal of Medical Virology973e70317
spellingShingle Susceptibility to lenacapavir among newly diagnosed HIV-positive patients followed up in Mozambique that presented with primary antiretroviral resistance to other classes
Sebastião, Cruz S.
drug resistance mutations
HIV-1
lenacapavir
Mozambique
status SINGLETON
subject.fl_str_mv drug resistance mutations
HIV-1
lenacapavir
Mozambique
title Susceptibility to lenacapavir among newly diagnosed HIV-positive patients followed up in Mozambique that presented with primary antiretroviral resistance to other classes
title_full Susceptibility to lenacapavir among newly diagnosed HIV-positive patients followed up in Mozambique that presented with primary antiretroviral resistance to other classes
title_fullStr Susceptibility to lenacapavir among newly diagnosed HIV-positive patients followed up in Mozambique that presented with primary antiretroviral resistance to other classes
title_full_unstemmed Susceptibility to lenacapavir among newly diagnosed HIV-positive patients followed up in Mozambique that presented with primary antiretroviral resistance to other classes
title_short Susceptibility to lenacapavir among newly diagnosed HIV-positive patients followed up in Mozambique that presented with primary antiretroviral resistance to other classes
title_sort Susceptibility to lenacapavir among newly diagnosed HIV-positive patients followed up in Mozambique that presented with primary antiretroviral resistance to other classes
topic drug resistance mutations
HIV-1
lenacapavir
Mozambique
topic_facet drug resistance mutations
HIV-1
lenacapavir
Mozambique
url http://hdl.handle.net/10400.26/63322
visible 1